Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol

  • Marie Lange1, 2, 3,
  • Heidi Laviec4,
  • Hélène Castel3, 5,
  • Natacha Heutte1, 2,
  • Alexandra Leconte2,
  • Isabelle Léger1, 3, 6, 7,
  • Bénédicte Giffard3, 8,
  • Aurélie Capel2,
  • Martine Dubois3, 5,
  • Bénédicte Clarisse2,
  • Elodie Coquan2, 4,
  • Frédéric Di Fiore9, 10,
  • Sophie Gouérant9, 10,
  • Philippe Bartélémy11,
  • Laure Pierard11,
  • Karim Fizazi12 and
  • Florence Joly1, 2, 3, 13Email author
BMC Cancer201717:549

https://doi.org/10.1186/s12885-017-3534-8

Received: 4 October 2016

Accepted: 3 August 2017

Published: 16 August 2017

Abstract

Background

New generation hormone-therapies (NGHT) targeting the androgen signalling pathway are nowadays proposed to elderly patients with metastatic castration-resistant prostate cancer (CRPCa). The impact of these treatments on cognitive function has never been evaluated whereas cognitive impairment may have an impact on the autonomy and the treatment adherence. The aim of this study is to prospectively assess the incidence of cognitive impairment in elderly men after treatment by NGHT for a metastatic CRPCa.

Methods/design

The Cog-Pro study is a multicentre longitudinal study including CRPCa patients ≥70 years old treated with NGHT (n = 134), control metastatic prostate cancer patients without castration resistance treated with first generation androgen deprivation therapy (n = 55), and healthy participants (n = 33), matched on age and education. Cognitive, geriatric and quality of life assessment and biological tests will be performed at baseline, 3, 6 and 12 months after start of the treatment (inclusion time). The primary endpoint is the proportion of elderly patients receiving a NGHT who will experience a decline in cognitive performances within 3 months after study enrollment. Secondary endpoints concern: autonomy, quality of life, anxiety, depression, cognitive reserve, adherence to hormone-therapy, comparison of the cognitive impact of 2 different NGHT (abiraterone acetate and enzalutamide), impact of co-morbidities and biological assessments.

Discussion

Evaluating, understanding and analyzing the incidence, severity of cognitive impairments and their impact on quality of life, autonomy and adherence in this group of patients with advanced disease is a challenge. This study should help to improve cancer care of elderly patients and secure the use of oral treatments as the risk of non-observance does exist. Our results will provide up-to date information for patients and caregivers on impact of these treatments on cognitive function in order to help the physicians in the choice of the treatment.

Trial registration

NCT02907372, registered: July 26, 2016.

Keywords

Cognitive impairments Ageing Prostate cancer Hormone therapy Adherence Quality of life

Background

Prostate cancer (PCa) is a major public health issue. It is the second most common cancer and the second leading cause of cancer-related death among men worldwide [1]. PCa incidence increases with age, peaking at 70 to 74 years of age and PCa thus represents the most frequent cancer among male elderly patients. Although most PCa patients with metastatic disease initially respond to androgen deprivation therapy (ADT) leading to inhibition of gonadal testosterone biosynthesis, the pathology in a majority of patients progresses within the 2 years to a metastatic castration-resistant prostate cancer (CRPCa) [2].

Novel oral agents targeting the androgen signalling pathway (abiraterone acetate or enzalutamide) are available and are now proposed to patients with metastatic CRPCa in addition to first generation ADT. These new generation hormone-therapies (NGHT) were shown to improve 2 to 4 months the median overall survival rate of asymptomatic or pauci-symptomatic patients with a metastatic CRPCa [3]. According to the clinical trials, the main reported adverse events of these treatments were fatigue, hot flashes and oedema. Nevertheless, the impact of these treatments on cognitive function should be evaluated through a battery of cognitive tests, in order to establish a comprehensive knowledge of the impact of hormone-therapy in this cancer patient population particularly at risk.

Because of the better profile of tolerability compared to chemotherapy, new oral hormone treatments are largely prescribed to elderly cancer patients. Aging by itself is associated with some cognitive modifications, co-morbidities and functional decline which may have an impact on the autonomy and quality of life. Preliminary results suggest that elderly cancer patients would be at greater risk for increased age-related brain changes secondary to cancer and cancer treatments [4, 5]. There are still many unresolved questions, including the characterization of subgroups at risk to develop cognitive dysfunctions with cancer treatments, the impact of comorbidities, and the specific effects of different cancer treatments such as hormone-therapies. Even if there are some evidence of the impact of chemotherapy on cognitive function [6, 7] and more particularly in elderly patients and animal subjects [8, 9], the real impact of hormone-therapy on cognition is not well understood [10] and there are still important gaps in our knowledge and understanding of the mechanisms associated with cognitive disorders, especially in elderly cancer patients.

Prior studies described cognitive dysfunctions after ADT for PCa patients who performed significantly worse on visuomotor tasks than controls [11] and showed a cognitive decline mainly in visuospatial abilities and executive functions [10, 12]. After all, this between 47 and 69% of ADT-treated male patients who experienced some degree of impairment in at least one cognitive domain [10]. These findings are consistent with the known beneficial effects of testosterone on cognitive functioning in men [13]. For example, higher free testosterone levels have been found to be associated with better performance on objective neuropsychological tests of visuospatial processing, visual memory, visuomotor scanning, visuospatial abilities and episodic memory in healthy community-based samples of older men [14, 15].

Most of the cognitive studies conducted in PCa patients focused on non-metastatic situation, had small sample size and the impact of the age and co-morbidities has not been evaluated.

There are some argues to expect that NGHT prescribed in metastatic castrate resistance setting may induce cognitive dysfunctions among this particular vulnerable group of patients. Abiraterone acetate is a selective androgen biosynthesis inhibitor in the testis and the adrenal gland. In order to avoid cortisol deficiency, the treatment is combined with chronic use of prednisone. However, it has been well described that exogenous administration of corticosteroid may induce decline of cognitive performance via effects on medial temporal lobe and prefrontal brain areas [16]. In addition, the molecule may have an impact on the synthesis of dehydroepiandrosterone that is implicated in cognition in elderly men [13]. Enzalutamide binds and inhibits androgen receptors that are also present in the brain, including regions than can be severely affected such as the cerebral cortex and the hippocampus [17]. Some seizures have been already described in clinical studies with enzalutamide [18]. In rodents, it has been shown that androgens increase spine synapse density in the prefrontal cortex and the hippocampus [19, 20] and that disruption of the androgen receptors activity has an impact on aggressive behaviour [21]. Together, these observations suggest that androgen deprivation and/or androgen receptor inhibition would accelerate the aging process of PCa elderly patients.

These new hormonal agents with a better profile of toxicity than chemotherapy should constitute a better disease care option for older patients, as long as they are exhaustively evaluated and studied. Indeed, they are delivered on long lasting in daily oral route, thus the chronically developing troubles and the complete adherence of the treatments, especially in patients with cognitive impairment [22] must be investigated.

Objectives

The purpose of the Cog-Pro study is to prospectively assess the incidence of cognitive impairment and cognitive complaints in elderly men (70 years old and over) after 3 months of treatment by NGHT for a metastatic CRPCa.

The secondary objectives are:
  • To compare the impact on cognitive function of the two new available hormonal agents (abiraterone acetate and enzalutamide)

  • To evaluate the impact of cognitive impairment on quality of life, autonomy and adherence to treatment,

  • To evaluate the relationship between objective cognitive impairment and self-reported complaints of the patients, taking into account the cognitive reserve, anxiety, depression, and fatigue,

  • To evaluate the relationship between co-morbidities, biological plasma markers and cognitive impairment.

Methods/design

The Cog-Pro study is a multicentre longitudinal study.

Three groups of participants are enrolled: (1) patients of interest (metastatic CRPCa treated with NGHT) and two groups of controls, i.e. (2) control metastatic PCa without castration resistance patients (treated with first generation of ADT) and (3) healthy participants. The two groups of controls were matched (2: 1) to patients of interest on age and education. Inclusion and exclusion criteria are listed in Table 1.
Table 1

Study inclusion and exclusion criteria

 

Patients of interest (metastatic CRPCa)

Control patients (metastatic PCa)

Healthy participants

Inclusion criteria

70-years old or more

70-years old or more

70-years old or more

Patient must have a metastatic CRPCa

Patient with metastatic prostate cancer without resistance to castration

Man with no history of cancer

Patient must have been already treated with first generation of ADT

Patient must have already started a first generation of ADT at least since 3 months

-

Patient must be candidate for a treatment by a NGHT (with abiraterone acetate or enzalutamide), in combination with ADT

-

-

Treatment with biphosphonates is authorized

-

-

Patient must have not received chemotherapy except one line per Docetaxel for hormono-sensitive situation and which must be completed for a least 18 months before inclusion

Patient must have not received chemotherapy except one line per Docetaxel for hormono-sensitive situation and which must be completed for a least 18 months before inclusion

-

OMS 0–2

OMS 0–2

Health status consistent with the participation to the study

Patient must be asymptomatic or pauci-symptomatic (with pain control, Visual Analog Scale ≤3)

Patient must be asymptomatic or pauci-symptomatic (with pain control, Visual Analog Scale ≤3)

-

No known brain metastasis

No known brain metastasis

-

At least on level 3 (end of primary schools) of the Barbizet scale

At least on level 3 (end of primary schools) of the Barbizet scale

At least on level 3 (end of primary schools) of the Barbizet scale

Exclusion criteria

Neurological sequelae of traumatic brain injury, stroke, multiple sclerosis, epilepsy, neuro-degenerative disease…

Personality disorders and known progressive psychiatric disorder

Drug use and/or heavy drinking

Assessed to be unable or unwilling to comply with the requirements of the protocol

Abbreviations: CRPCa castration-resistant prostate cancer, ADT androgen deprivation therapy, NGHT new generations of hormone-therapy

The patients of interest will be selected by physicians who will propose the study to the patients’ candidate for a NGHT according to the guidelines and the drug authorizations. The control group of patients will be selected by the medical oncologists and matched on age and education to the group of patients of interest.

The two groups of patients will be recruited in Cancer Comprehensive Centres for 2 years and during 1 year follow up. The healthy participants will be recruited from the general population through retirement associations, a senior university or an advertisement in Cancer Comprehensive Centres (husband of patients), for example. Participants enrolled in the study provide their written informed consent.

Assessments

For all the participants, assessments will be conducted, once signed the consent form, at inclusion - baseline - (for patients of interest: before the start of the treatment or within 7 days after the start of treatment), 3, 6 and 12 months (Fig. 1).
Fig. 1

Study flowchart

Cognitive tests, questionnaires and biological tests used for assessments are listed in Table 2.
Table 2

Used cognitive tests, questionnaires and biological tests

Evaluations

Before inclusion

At inclusion (baseline)a

3 months

6 months

12 months

Signed Informed Consent

    

Previous medical history

    

Cognitive assessmentb

 MoCA

     

 Grober-Buschke test

     

 Digit span forward and backward (WAIS-III)

 

 Code (WAIS III)

     

 Trail Making test

     

 Doors test

     

 Stroop Victoria

     

 Verbal fluencies

     

 Rey-Osterrieth Complex Figure

     

 Number location (VOSP)

     

 Years of education and fNART

 

Only at inclusion

   

Quality of life

 FACT-G, FACIT-F, FACT-Cog, HADS, ISI

 

Pain (VAS)

a

ONLY for PATIENTS (group of interest and control group)

Geriatric assessmentc

 G8

     

 Charlson

     

 ADL

 

 IADL

     

 MNA

     

 Time up and go

     

Quality of life

 FACT-P

 

Adherence evaluationd

 Morisky questionnaire

  

 Patient diary

     

Biological testsc

 

Specific blood samples for further researche

 

   

MoCA Montreal Cognitive Assessment, WAIS Wechsler Adult Intelligence Scale, VOSP Visual Object and Space Perception Battery, fNART French National Adult Reading Test, ISI Insomnia Severity Index, VAS Visual Analog Scale, ADL Activities of Daily Living, IADL Instrumental Activities of Daily Living, MNA Mini-Nutritional Assessment

aFor group of interest patients: before the start of the treatment or within 7 days after the start of treatment by abiraterone acetate or enzalutamide

bCognitive assessment will be performed by neuropsychologists

cGeriatric assessment will be performed by a study nurse specialized in geriatric

dHad to be ≤ 3 on the 0–10 pain VAS scale to meet with inclusion pain criteria

eAdherence evaluation will be performed only in group of interest patients

fAt each time: CBC, platelets, albumin, CRP, prealbumin, iron, ferritin, transferrin, creatinin, sodium, potassium, ALT, AST, GGT, ALP, total bilirubin, TSH, T4, testosterone. At inclusion only: cortisol (at 8 hours AM, fasting)

g1 EDTA (5 ml), 1 dry tube with gel (5 ml) and 1 dry tube without gel (5 ml)

At inclusion, previous medical history will be reported as well as relevant medications (psychotropic, opioids…).

Cognitive assessment

Objective cognitive function will be evaluated by the International Cognition and Cancer Taskforce (ICCTF) recommended battery of tests [7] and taking into account the previously observed cognitive impairment with ADT for PCa patients [10, 23]. The full evaluation will take less than one hour and will be performed by a neuropsychologist.

Global cognitive efficiency will be assessed by the Montreal Cognitive Assessment (MoCA: a rapid screening instrument for cognitive impairment) [24].

The main explored domains are visuo-spatial ability, episodic memory, working memory, executive functions and information processing speed (Rey-Osterrieth Complex Figure [25], number location (Visual Object and Space Perception battery - VOSP [26]), Grober-Buschke test [27], Doors test [28], digit span forward and backward (Wechsler Adult Intelligence Scale - WAIS III [29])), Trail Making test [30], verbal fluencies [31], Stroop Victoria [32], Code (WAIS III [29]). Proxies for cognitive reserve will include years of education and French National Adult Reading Test (fNART [33]).

Quality of life, adherence and pain assessment

We will use validated self-report questionnaires to evaluate global quality of life (Functional Assessment of Cancer Therapy-General: FACT-G [34]), fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue: FACIT-F [35]), the prostate specific symptoms (Functional Assessment of Cancer Therapy-Prostate: FACT-P [36]), cognitive complaints (Functional Assessment of Cancer Therapy Cognitive Scale: FACT-Cog [37]), depression and anxiety (Hospital Anxiety and Depression Scale: HADS [38]) and quality of sleep (Insomnia Severity Index: ISI [39]).

We will combine subjective and objective measures to optimize the evaluation of adherence (assessed only in patients of interest). Adherence will be subjectively evaluated by a validated self-report questionnaire: the Morisky Medication Adherence Scale (MMAS) [40], 6-items French version [41] and objectively assessed by a patient diary.

Pain will be prospectively assessed with the Visual Analog Scale (VAS).

Geriatric assessment

Geriatric assessment will be performed by a study nurse in geriatric. The assessment consists of the G8 screening tool [42], the Charlson comorbidity index [43], the Activities of Daily Living (ADL [44]), the Instrumental Activities of Daily Living (IADL [45]), Mini-Nutritional Assessment (MNA [46]), Time up and go test [47].

Biological tests and biological collection

Biological tests will be performed only in the 2 groups of patients (Table 2). Specific blood samples (for plasma preparation) for the research will be collected at inclusion for constitution of a collection in patients who have giving their agreement on consent form (the specific blood sample is optional in the study).

Primary and secondary endpoints

The primary endpoint is the proportion of elderly patients receiving the NGHT who will experience a decline in cognitive performances (at least for one cognitive domain) within 3 months after inclusion.

The secondary endpoints will be based on:
  • cognitive functioning (objective cognitive performances and self-report complaints),

  • the comparison of the impact of the 2 new agents (abiraterone acetate and enzalutamide) on cognition,

  • autonomy, quality of life, anxiety, depression and cognitive reserve,

  • adherence to hormone-therapy,

  • co-morbidities and biological assessments.

Statistical analysis

Sample size

  • Patients of interest (receiving NGHT)

Assuming between 47 and 69% of men who received ADT experience some degree of impairment in at least one cognitive domain [10], we hypothesise that 50% of patients will decline on cognitive performances.

To estimate the range of exact confidence interval (90%) with an accuracy of 7.5%, 121 assessable patients are required. To anticipate 10% of non-assessable patients, we plan to enrol 13 additional patients, for a total of 134 patients.

Given the secondary objective aiming at comparing the incidence of patients with cognitive decline between each available NGHT, study population will be constituted by:
  • 50% of patients (i.e. 67 patients) receiving abiraterone acetate

  • 50% of patients (i.e. 67 patients) receiving enzalutamide

With these sample sizes, it will be possible to detect (α = 5%; 1-β = 80%, bilateral test) some significant differences in proportions of patients with cognitive decline for the following proportions (π1, π2) or significant differences between patients and healthy participants.
  • Control groups

In addition, two control groups matched on age and education with patients of interest will be included in order to have some neuropsychological data of reference:
  • 55 control patients receiving ADT for metastatic PCa without castration resistance (Control patients),

  • 33 healthy men (Healthy participants).

Planned analysis

Statistical tests and confidence intervals will be calculated with an overall error significance level of 5%. The proportion of elderly patients treated with NGHT who will experience a decline of cognitive functions (at least in one cognitive domain) between baseline and 3 months will be presented with its exact confidence interval.

The repeated measures analysis will be done using a mixed model.

Change in cognitive function will be determined, as recommended by ICCTF [7], using the standardized regression-based (SRB) approach used by Stewart et al. [48] and proposed by McSweeny et al. [49] and Sawrie et al. [50].

The secondary endpoints are based on quantitative scores of cognitive functions, quality of life, autonomy and geriatric frailty. Summary of score statistics and their significant variations from baseline will be calculated at each assessment time point for each group. The mean (and 95% confidence interval) and median (and min-max) of the absolute scores and changes from baseline will be reported.

Relationship between the objective cognitive impairment and following covariates:
  1. 1.

    autonomy, quality of life, anxiety, depression, fatigue, cognitive complaints, and cognitive reserve,

     
  2. 2.

    adherence to hormone-therapy,

     
  3. 3.

    two new agents (abiraterone acetate and enzalutamide),

     
  4. 4.

    co-morbidities and biological assessments,

     

will be assessed using a mixed model in order to compare change over time among the patient groups and healthy participants.

Discussion

Due to the high incidence of prostate cancer, the increase of the life expectancy and the recent availability of NGHT for advanced prostate cancer, there is a dramatic increase of the number of elderly patients who are proposed to be treated for metastatic CRPCa. As these treatments improve the survival rate only of few months, it is very important to more extensively explore all their potential side-effects, especially in elderly patients. One major issue in this group of patients is to maintain autonomy and quality of life as long as possible, and this depends in a large part on their cognitive function at the baseline and during the period of cancer treatment.

We will conduct the first study evaluating cognitive function among elderly patients with metastatic CRPCa who will beneficiate from NGHT. By the end of the project, we should have assembled the complete information package on elderly patients at risk of cognitive decline with these new treatments. If we find that these treatments induce cognitive declines, it would be an important point to put into the balance of risk/efficacy of the treatments, and this point will have to be discussed with the patients. Also, it will provide opportunity to reinforce the follow-up of the adherence (i.e. follow-up by a clinician nurse for example). This research should therefore play a part in providing information as accurate as possible to the patients in term of quality of life, fatigue and emotional state during the treatment. Thus, a complete study to evaluate these cognitive impairments in elderly patients is necessary for maintaining a good quality of life in palliative situations.

This original study should help to better respond to some objectives of the third French cancer plan, such as improving cancer care of elderly patients and considering the specificities of this population, securing the use of oral treatments as the risk of non-observance does exist, taking into account and better understanding side effects of the treatments, such as memory and attention deficits.

Conclusion

Evaluating, understanding and analyzing the incidence, severity of cognitive impairments and their impact on quality of life, autonomy and adherence among prostate cancer patients with advanced disease is a challenge. This study should help to improve cancer care of elderly patients and secure the use of oral treatments as the risk of non-observance does exist. Our results will provide up-to date information for patients and caregivers on impact of new generation hormone-therapies on cognitive function in order to help the physicians in the choice of the treatment and could promote the development of cognitively safe treatments.

Abbreviations

ADT: 

Androgen Deprivation Therapy

CRPCa: 

Castration-Resistant Prostate Cancer

NGHT: 

New generation hormone-therapies

PCa: 

Prostate cancer

Declarations

Acknowledgements

None.

Funding

This work is supported by the French Institut National du Cancer (InCA_9528) for the collection of data and by a specific donation from ASTELLAS.

Availability of data and materials

Not applicable.

Authors’ contributions

ML, HC, BG and FJ wrote the manuscript and devised the study concept and design. NH was responsible for overseeing the statistical section. All authors (ML, HL, HC, NH, AL, IL, BG, AC, MD, BC, EC, FDF, SG, PB, LP, KF, FJ) contributed to the study protocol, read and approved the final manuscript.

Ethics approval and consent to participate

This study has received ethical approval from the Comité de Protection des Personnes de Nord Ouest III in Avril 2016 and from National Agency for Medical and Health products Safety (Reference: 2016–001248-20). All patients gave their informed consent before any study-related assessment was started.

Consent for publication

Not applicable

Competing interests

FJ received donation from ASTELLAS to conduct this study.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
INSERM, U1086 ANTICIPE, Normandie University, UNICAEN
(2)
Clinical Research Department, Centre François Baclesse
(3)
Cancer and Cognition Platform, Ligue Nationale Contre le Cancer
(4)
Medical Oncology Department, Centre François Baclesse
(5)
Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Normandie University, UNIROUEN, INSERM, DC2N
(6)
UPO, Gustave Roussy
(7)
NeuroHIV Rehabilitation Unit, Bicêtre University Hospital
(8)
Normandie University, UNICAEN, EPHE Paris, INSERM, U1077
(9)
Medical Oncology Department, Centre Henri-Becquerel
(10)
Digestive and Urology Oncology Unit, Rouen University Hospital
(11)
Medical Oncology and Hematology Department, Hôpitaux Universitaires de Strasbourg
(12)
Medical Oncology Department, Gustave Roussy
(13)
Medical Oncology Department, CHU de Caen

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.View ArticlePubMedGoogle Scholar
  2. Loriot Y, Massard C, Fizazi K. Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. Ann Oncol. 2012;23(5):1085–94.View ArticlePubMedGoogle Scholar
  3. Armstrong AJ. New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps? Eur Urol. 2014;65(2):300–2.View ArticlePubMedGoogle Scholar
  4. Lange M, Rigal O, Clarisse B, Giffard B, Sevin E, Barillet M, Eustache F, Joly F. Cognitive dysfunctions in elderly cancer patients: a new challenge for oncologists. Cancer Treat Rev. 2014;40(6):810–7.View ArticlePubMedGoogle Scholar
  5. Lange M, Giffard B, Noal S, Rigal O, Kurtz JE, Heutte N, Levy C, Allouache D, Rieux C, Fel JL, Daireaux A, Clarisse B, Veyret C, Barthelemy P, Longato N, Eustache F, Joly F. Baseline cognitive functions among elderly patients with localised breast cancer. Eur J Cancer. 2014;50:2181–9.View ArticlePubMedGoogle Scholar
  6. Joly F, Giffard B, Rigal O, de Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancre V, Lange M, Castel H. Impact of cancer and its treatments on cognitive function: advances in research from the Paris international cognition and cancer task force symposium and update since 2012. J Pain Symptom Manag. 2015;50(6):830–41.View ArticleGoogle Scholar
  7. Wefel JS, Vardy J, Ahles T, Schagen SB. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–8.View ArticlePubMedGoogle Scholar
  8. Dubois M, Lapinte N, Villier V, Lecointre C, Roy V, Tonon MC, Gandolfo P, Joly F, Hilber P, Castel DH. Chemotherapy-induced long-term alteration of executive functions and hippocampal cell proliferation: role of glucose as adjuvant. Neuropharmacology. 2014;79:234–48.View ArticlePubMedGoogle Scholar
  9. Lange M, Heutte N, Rigal O, Noal S, Kurtz JE, Levy C, Allouache D, Rieux C, Fel JL, Clarisse B, Veyret C, Barthelemy P, Longato N, Castel H, Eustache F, Giffard B, Joly F. Decline in cognitive functions in elderly early-stage breast cancer patients after adjuvant treatment. Oncologist. 2016;21(11):1337–48.Google Scholar
  10. Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113(5):1097–106.View ArticlePubMedPubMed CentralGoogle Scholar
  11. McGinty HL, Phillips KM, Jim HS, Cessna JM, Asvat Y, Cases MG, Small BJ, Jacobsen PB. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer. 2014;22(8):2271–80.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Donovan KA, Walker LM, Wassersug RJ, Thompson LM, Robinson JW. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer. 2015;121(24):4286–99.View ArticlePubMedGoogle Scholar
  13. Maggio M, Dall’Aglio E, Lauretani F, Cattabiani C, Ceresini G, Caffarra P, Valenti G, Volpi R, Vignali A, Schiavi G, Ceda GP. The hormonal pathway to cognitive impairment in older men. J Nutr Health Aging. 2012;16(1):40–54.View ArticlePubMedGoogle Scholar
  14. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002;87(11):5001–7.View ArticlePubMedGoogle Scholar
  15. Thilers PP, Macdonald SW, Herlitz A. The association between endogenous free testosterone and cognitive performance: a population-based study in 35 to 90 year-old men and women. Psychoneuroendocrinology. 2006;31(5):565–76.View ArticlePubMedGoogle Scholar
  16. Young KD, Preskorn SH. Neuroscientific basis of corticosteroid-induced changes in human cognitive and emotional processing: implications for affective illness. J Psychiatr Pract. 2013;19(4):309–15.View ArticlePubMedGoogle Scholar
  17. Fuller SJ, Tan RS, Martins RN. Androgens in the etiology of Alzheimer’s disease in aging men and possible therapeutic interventions. J Alzheimers Dis. 2007;12(2):129–42.View ArticlePubMedGoogle Scholar
  18. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.View ArticlePubMedGoogle Scholar
  19. Leranth C, Petnehazy O, MacLusky NJ. Gonadal hormones affect spine synaptic density in the CA1 hippocampal subfield of male rats. J Neurosci. 2003;23(5):1588–92.PubMedGoogle Scholar
  20. Hajszan T, MacLusky NJ, Johansen JA, Jordan CL, Leranth C. Effects of androgens and estradiol on spine synapse formation in the prefrontal cortex of normal and testicular feminization mutant male rats. Endocrinology. 2007;148(5):1963–7.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Raskin K, de Gendt K, Duittoz A, Liere P, Verhoeven G, Tronche F, Mhaouty-Kodja S. Conditional inactivation of androgen receptor gene in the nervous system: effects on male behavioral and neuroendocrine responses. J Neurosci. 2009;29(14):4461–70.View ArticlePubMedGoogle Scholar
  22. Fung C, Dale W, Mohile SG. Prostate cancer in the elderly patient. J Clin Oncol. 2014;32(24):2523–30.View ArticlePubMedGoogle Scholar
  23. Agrawal K, Onami S, Mortimer JE, Pal SK. Cognitive changes associated with endocrine therapy for breast cancer. Maturitas. 2010;67(3):209–14.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.View ArticlePubMedGoogle Scholar
  25. Rey A. Manual of copy and memory reproduction test of complexe geometric figures. Paris: Éditions Centre de psychologie appliquée; 1959.Google Scholar
  26. Herrera-Guzman I, Pena-Casanova J, Lara JP, Gudayol-Ferre E, Bohm P. Influence of age, sex, and education on the visual object and space perception battery (VOSP) in a healthy normal elderly population. Clin Neuropsychol. 2004;18(3):385–94.View ArticlePubMedGoogle Scholar
  27. Van der Linden M, Adam S, Agniel A, Ntérion-Thomas C, Baisset-Mouly C, Coyette F, et al. Assessment of memory impairment. Marseille: Solal; 2004.Google Scholar
  28. Baddeley A, Esmlie H, Nimmo-Smith I. The doors and people test. Bury St Edmunds, England: Thames Valley Test Company; 2006.Google Scholar
  29. Wechsler D. [Wechsler Adult Intelligence Scale-III]. Paris: ECPA; 2000.Google Scholar
  30. Reitan R. Validity of trail making tests as an indicator of organic brain damage. Percept Motor Skills. 1958;8:271–6.View ArticleGoogle Scholar
  31. Cardebat D, Doyon B, Puel M, Goulet P, Joanette Y. Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg. 1990;90(4):207–17.PubMedGoogle Scholar
  32. Moroni C, Bayard S. Inhibitory process: what evolution after the age of 50? Psychol Neuropsychiatr Vieil. 2009;7(1):1–9.Google Scholar
  33. Nelson HE, O’Connell A. Dementia: the estimation of premorbid intelligence levels using the new adult reading test. Cortex. 1978;14(2):234–44.View ArticlePubMedGoogle Scholar
  34. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.View ArticlePubMedGoogle Scholar
  35. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13(2):63–74.View ArticleGoogle Scholar
  36. Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the functional assessment of cancer therapy-prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health. 2009;12(1):124–9.Google Scholar
  37. Joly F, Lange M, Rigal O, Correia H, Giffard B, Beaumont JL, Clisant S, Wagner L. French version of the functional assessment of cancer therapy-cognitive function (FACT-cog) version 3. Support Care Cancer. 2012;20(12):3297–305.View ArticlePubMedGoogle Scholar
  38. Razavi D, Delvaux N, Farvacques C, Robaye E. Screening for adjustment disorders and major depressive disorders in cancer in-patients. Br J Psychiatry. 1990;156:79–83.View ArticlePubMedGoogle Scholar
  39. Gagnon C, Belanger L, Ivers H, Morin CM. Validation of the insomnia severity index in primary care. J Am Board Fam Med. 2013;26(6):701–10.View ArticlePubMedGoogle Scholar
  40. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich ). 2008;10(5):348–54.View ArticleGoogle Scholar
  41. Girerd X, Hanon O, Anagnostopoulos K, Ciupek C, Mourad JJ, Consoli S. Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic. Presse Med. 2001;30(21):1044–8.Google Scholar
  42. Soubeyran P, Bellera C, Goyard J, Heitz D, Cure H, Rousselot H, Albrand G, Servent V, Jean OS, van Praagh I, Kurtz JE, Perin S, Verhaeghe JL, Terret C, Desauw C, Girre V, Mertens C, Mathoulin-Pelissier S, Rainfray M. Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study. PLoS One. 2014;9(12):e115060.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.View ArticlePubMedGoogle Scholar
  44. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist. 1970;10(1):20–30.View ArticlePubMedGoogle Scholar
  45. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–86.View ArticlePubMedGoogle Scholar
  46. Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: the mini nutritional assessment as part of the geriatric evaluation. Nutr Rev. 1996;54(1 Pt 2):S59–65.PubMedGoogle Scholar
  47. Podsiadlo D, Richardson S. The timed “up & go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8.View ArticlePubMedGoogle Scholar
  48. Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psycho-Oncology. 2008;17(2):122–30.View ArticlePubMedGoogle Scholar
  49. McSweeney AJ, Naugle RI, Chelune GJ, Lunders H. “T scores for change”: an illustration of a regression approach to depicting change in clinical neuropsychology. Clin Neuropsychol. 1993;7:300–12.View ArticleGoogle Scholar
  50. Sawrie SM, Marson DC, Boothe AL, Harrell LE. A method for assessing clinically relevant individual cognitive change in older adult populations. J Gerontol B Psychol Sci Soc Sci. 1999;54(2):116–24.View ArticleGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement